Mass spectroscopy seminar: Da­ni­el Glo­bisch - "New bio­mar­ker dis­co­very ap­proa­ches for pan­crea­tic can­cer"

There will be a small reception with wine and cheese after the seminar (sponsored by Thermo Fisher Scientific and Bruker Daltonics).

 

Pancreatic cancer is one of the most lethal cancer type worldwide with very low survival rates due to the absence of sensitive and reliable diagnostic tools for an early detection. The discovery of unknown early-stage biomarkers for pancreatic cancer is urgently required and the impact of host-microbiome interactions for the development of pancreatic cancer on a molecular level is still unknown. Analysis of metabolites in any type of human specimen comprises a high potential for the identification of unknown biomarkers. Our interdisciplinary projects are focussed on the development of new methodologies using techniques at the interface of chemistry and biology for an advanced quantitative and qualitative mass spectrometric analysis to discover disease-specific metabolites. These new methodologies are aimed at enhancing the scope of mass spectrometry-based metabolomics research and simplifying biomarker discovery. Validated specific early-stage biomarkers are a crucial first step for the development of new diagnostics, which would allow for improved and more efficient therapeutic interventions.

 

New: Follow us on Twitter: @Bremen_MassSpec